Genolution

Genolution Forward P/E

The Forward P/E Ratio of Genolution (225220.KQ) as of Oct 22, 2026 is -2.81. In the previous year, Forward P/E Ratio was -4.79 — a change of -41.37% (higher).

Forward P/E

-2.81

YoY

-41.37%

Last updated:

Forward P/E Ratio of Genolution is 2025 -2.81 . Forward P/E Ratio of Genolution was 2024 -4.79 . It decreases by -41.37% higher compared to the previous year.

The Genolution Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
25.31 KRW
Jan 1, 2019
-113.94 KRW
Jan 1, 2020
1.02 KRW
Jan 1, 2021
0.95 KRW
Jan 1, 2022
2.24 KRW
Jan 1, 2023
-5.89 KRW
Jan 1, 2024
-4.79 KRW
Jan 1, 2025
-2.81 KRW
The Genolution Forward P/E history
YEARForward P/EYoY
-2.81-41.37%
-4.79-18.68%
-5.89-363.08%
2.24+135.55%
0.95-6.83%
1.02-100.90%
-113.94-550.21%
25.31-55.34%
56.67-84.74%
371.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Forward P/E Ratio of Genolution is -2.81 in 2025.

Forward P/E Ratio of Genolution changed from -4.79 to -2.81, representing a -41.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genolution

All Key Metrics — Genolution